In other news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62 ...

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $55.62 ...

Analysts predict that CRISPR Therapeutics AG will post -5.13 EPS for the current year. In related news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction dated ...

In other news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in ...

According to the company's Chairman and CEO, Samarth Kulkarni, Ph.D., CRISPR Therapeutics aims to build on the successful launch of CASGEVY®, expanding its portfolio to include treatments for ...

a strong balance sheet and an organizational foundation to drive our pipeline forward,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Building on ...

said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Building on the success of CASGEVY’s launch, we continue to broaden our portfolio across ...

In other news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value ...

a strong balance sheet and an organizational foundation to drive our pipeline forward,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. "Building on the ...